Thyroid cancer represents approximately 1% of new cancer and oestrogen may play a role in the pathogenesis of thyroid neoplasm. We aimed to study the clinicopathological criteria and ER expression of thyroid cancer in Mansoura University (Egypt), and to correlate the survival to these clinicopathological data and ER expression. This retrospective study reviewed 644 patients with histologically proven thyroid carcinoma during the period from 2003 to 2011. 152 cases during the period between 2008 and 2011 were retrieved from the archive and examined by immunohistochemistry for oestrogen receptor-α (ER) expression. ER-α expression is significantly associated with the female sex, lymph node metastasis, TNM stage, extrathyroid extension, multifocality disease and recurrence and in the whole series (p < 0.5). The same was noticed in papillary carcinoma (PTC) except the gender of the patient. Tumour type, extrathyroid extension and ER expression were the independent prognostic factors of DFS, while in PTC, only ER expression was the independent one. The histological type was the only independent prognostic factor for OAS in the series were studied for ER expression, while extrathyroid extension was the only one that affected OAS of PTC. There was significant positive correlation with lymph node metastasis and ER expression in whole patient and PTC cases. No difference in survival between the low and high ranges of positive oestrogen expression. The prognosis of thyroid carcinoma in Egypt is similar to that occurs worldwide. ER-α expression was a significant prognostic marker for DFS in thyroid cancer and can be used as a predictive factor of lymph node metastasis.
Background: Obesity is a well-known risk factor for many health problems including endometrial cancer. In addition, it may act as an obstacle to achieving optimal treatment of endometrial cancer and may be associated with disease recurrence. Aim: To explore the impact of obesity on the operative procedure, recurrence of disease and survival in patients with endometrial cancer. Methods: A retrospective study of 267 patients with endometrial carcinoma who underwent surgery at the Oncology Center-Mansoura University from January 2011 to December 2017. Patients were divided according to their body mass index (BMI) into two groups, Group 1 with a BMI <30 and Group 2 with a BMI ≥30. Results: Group 1 included 46 patients and Group 2 included 221. The mean operative time was longer in Group 2 without statistically significant difference. Twenty-two (47.8%) patients in Group 1 and 71 (32.1%) in Group 2 underwent lymphadenectomy (p=0.062). The estimated blood loss was significantly higher in Group 2 (p<0.05). No statistically significant difference was found between the two groups regarding the intra or post-operative complications, despite the high incidence of complications in Group 2. The median disease-free survival (DFS) was 74 months in Group 1 vs. 66 months in Group 2. Obesity did not have a statistically significant impact on DFS among the studied cases (p=0.24).
Conclusion:In the current study, obesity did not significantly impact the operative procedure, surgical complications or DFS in patient with endometrial cancer.
while high-risk endometrial cancer includes women with stage III or higher Endometrial Cancer, regardless of histology or grade. A Serous Carcinoma, Clear Cell Carcinoma, and Carcinosarcoma are considered at high risk, regardless of the stage. An Intermediate risk includes all others (Colombo et al., 2016). The use of Pelvic external beam radiotherapy has been for many years the standard treatment for high-risk Endometrial Cancer. Patients treated with pelvic radiotherapy showed a delay
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.